ESSA Pharma Inc. (NASDAQ:EPIX - Get Free Report) TSE: EPI's stock price crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $2.66 and traded as low as $1.60. ESSA Pharma shares last traded at $1.61, with a volume of 40,449 shares changing hands.
Wall Street Analyst Weigh In
Several research firms have issued reports on EPIX. Oppenheimer lowered shares of ESSA Pharma from an "outperform" rating to a "market perform" rating in a research report on Monday, November 4th. Jefferies Financial Group downgraded shares of ESSA Pharma from a "buy" rating to a "hold" rating in a research note on Monday, November 4th. Finally, Piper Sandler cut ESSA Pharma from an "overweight" rating to a "neutral" rating and reduced their price target for the stock from $15.00 to $2.00 in a report on Monday, November 4th.
View Our Latest Stock Report on EPIX
ESSA Pharma Price Performance
The firm has a market capitalization of $71.47 million, a P/E ratio of -2.60 and a beta of 1.63. The firm has a 50 day moving average of $2.57 and a 200-day moving average of $4.46.
ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI last released its earnings results on Tuesday, December 17th. The company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.05. As a group, research analysts expect that ESSA Pharma Inc. will post -0.7 EPS for the current year.
Insiders Place Their Bets
In other ESSA Pharma news, major shareholder Growth N. V. Biotech sold 7,879,583 shares of the company's stock in a transaction on Friday, November 1st. The stock was sold at an average price of $1.53, for a total transaction of $12,055,761.99. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 14.70% of the company's stock.
Hedge Funds Weigh In On ESSA Pharma
An institutional investor recently raised its position in ESSA Pharma stock. Parkman Healthcare Partners LLC raised its holdings in ESSA Pharma Inc. (NASDAQ:EPIX - Free Report) TSE: EPI by 37.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 345,902 shares of the company's stock after acquiring an additional 93,830 shares during the period. Parkman Healthcare Partners LLC owned about 0.78% of ESSA Pharma worth $2,096,000 at the end of the most recent quarter. Institutional investors own 75.12% of the company's stock.
About ESSA Pharma
(
Get Free Report)
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
Further Reading
Before you consider ESSA Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ESSA Pharma wasn't on the list.
While ESSA Pharma currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
